ABMT (Advanced BioMedical Technologies) EBIT: $-0.44 Mil (TTM As of Jul. 2021)


What is Advanced BioMedical Technologies EBIT?

Advanced BioMedical Technologies ABMT EBIT is $-0.44 Mil as of Jul. 2021.

Advanced BioMedical Technologies's earnings before interest and taxes (EBIT) for the three months ended in Jul. 2021 was $-0.12 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jul. 2021 was $-0.44 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Advanced BioMedical Technologies's annualized ROC % for the quarter that ended in Jul. 2021 was -263.53%. Advanced BioMedical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2021 was -297.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Advanced BioMedical Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2021 was -1,020.93%.

Advanced BioMedical Technologies  (OTCPK:ABMT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Advanced BioMedical Technologies's annualized ROC % for the quarter that ended in Jul. 2021 is calculated as:

ROC % (Q: Jul. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2021 ) + Invested Capital (Q: Jul. 2021 ))/ count )
=-0.448 * ( 1 - 0% )/( (0.175 + 0.165)/ 2 )
=-0.448/0.17
=-263.53 %

where

Invested Capital(Q: Apr. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.379 - 8.334 - ( 0.006 - max(0, 8.348 - 0.218+0.006))
=0.175

Invested Capital(Q: Jul. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.397 - 8.568 - ( 0.007 - max(0, 8.579 - 0.243+0.007))
=0.165

Note: The Operating Income data used here is four times the quarterly (Jul. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Advanced BioMedical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2021  Q: Jul. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.468/( ( (0.161 + max(-8.175, 0)) + (0.154 + max(-8.379, 0)) )/ 2 )
=-0.468/( ( 0.161 + 0.154 )/ 2 )
=-0.468/0.1575
=-297.14 %

where Working Capital is:

Working Capital(Q: Apr. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.159 + 0) - (8.334 + 0 + 1.7763568394003E-15)
=-8.175

Working Capital(Q: Jul. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.189 + 0) - (8.568 + 0 + 1.7763568394003E-15)
=-8.379

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Advanced BioMedical Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jul. 2021 )
=-0.439/0.043
=-1,020.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies EBIT Related Terms

Advanced BioMedical Technologies EBIT Historical Data

* Premium members only.

The historical data trend for Advanced BioMedical Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies EBIT Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 -0.43 -0.65 -0.62 -0.34

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.12 -0.10 -0.11 -0.12

ABMT vs VYCO, ADMT, THMO: EBIT Comparison

For the Medical Devices subindustry, Advanced BioMedical Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced BioMedical Technologies EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's EV-to-EBIT falls into.


Advanced BioMedical Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jul. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.44 Mil mean?
Advanced BioMedical Technologies (ABMT) has a EBIT of $-0.44 Mil as of Jul. 2021. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advanced BioMedical Technologies.
Is Advanced BioMedical Technologies' EBIT too high?
Advanced BioMedical Technologies' current EBIT is $-0.44 Mil.
How does Advanced BioMedical Technologies' EBIT compare to VYCO and ADMT?
Advanced BioMedical Technologies' EBIT of $-0.44 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advanced BioMedical Technologies. Advanced BioMedical Technologies's current EBIT is $-0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current EBIT of $-0.44 Mil. The current EBIT is $-0.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current EBIT is $-0.44 Mil as of Jul. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced BioMedical Technologies Business Description

Address 535 Fifth Avenue, 4th Floor, New York, NY, USA, 10017
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.